Pneumonia (Haemophilus influenzae type b - Hib)

Overview


Plain-Language Overview

Pneumonia (Haemophilus influenzae type b - Hib) is an infection that affects the lungs, causing inflammation and difficulty breathing. It is caused by the bacterium Haemophilus influenzae type b, which primarily targets the respiratory system. This infection can lead to symptoms such as cough, fever, and chest pain. The lungs become filled with fluid and immune cells, making it hard for oxygen to pass into the blood. This condition is especially serious in young children and can cause severe illness if not treated promptly. The infection can spread from the lungs to other parts of the body, leading to complications. Overall, it significantly impacts breathing and oxygen delivery to the body.

Clinical Definition

Pneumonia (Haemophilus influenzae type b - Hib) is a bacterial infection characterized by inflammation of the lung parenchyma caused by Haemophilus influenzae type b. The pathogen colonizes the upper respiratory tract and invades the lower respiratory tract, leading to alveolar inflammation and consolidation. This results in impaired gas exchange and respiratory symptoms such as productive cough, fever, and dyspnea. Hib pneumonia is a major cause of morbidity and mortality in unvaccinated children and immunocompromised individuals. The infection can progress to complications like pleural effusion and bacteremia. Diagnosis and management are critical to prevent severe outcomes and systemic spread.

Inciting Event

  • Inhalation of respiratory droplets containing Hib from an infected or colonized individual initiates infection.

  • Recent viral upper respiratory infection can disrupt mucosal barriers facilitating Hib invasion.

  • Exposure to unvaccinated carriers in close-contact settings triggers disease onset.

Latency Period

  • Incubation period typically ranges from 2 to 4 days after exposure to Hib.

  • Symptom onset usually occurs rapidly following bacterial colonization and invasion.

Diagnostic Delay

  • Non-specific early symptoms such as cough and fever may mimic viral infections, delaying diagnosis.

  • Lack of vaccination history awareness can lead to underestimation of Hib risk.

  • Empiric treatment without microbiologic confirmation may obscure diagnosis.

  • Limited access to blood culture or sputum culture delays pathogen identification.

Clinical Presentation


Signs & Symptoms

  • High fever and chills

  • Productive cough with purulent sputum

  • Pleuritic chest pain worsened by deep breathing or coughing

  • Dyspnea and tachypnea

  • Fatigue and malaise

History of Present Illness

  • Acute onset of high fever and productive cough is typical in Hib pneumonia.

  • Rapid progression to respiratory distress and tachypnea may occur in severe cases.

  • Pleuritic chest pain and malaise are common accompanying symptoms.

  • Possible preceding upper respiratory symptoms such as rhinorrhea or sore throat.

Past Medical History

  • Incomplete or absent Hib vaccination is a critical factor in disease susceptibility.

  • History of recent viral respiratory infection may predispose to secondary bacterial pneumonia.

  • Chronic pulmonary diseases such as asthma or bronchopulmonary dysplasia increase risk.

  • Immunodeficiency disorders or splenectomy history are relevant predisposing conditions.

Family History

  • There are no well-established hereditary patterns associated with Hib pneumonia.

  • Familial immunodeficiency syndromes may increase susceptibility to invasive bacterial infections.

  • Close household contacts with unvaccinated individuals increase transmission risk.

Physical Exam Findings

  • Fever and tachypnea indicating systemic infection and respiratory distress

  • Crackles (rales) and bronchial breath sounds over affected lung fields

  • Dullness to percussion suggesting consolidation

  • Increased tactile fremitus over consolidated lung areas

  • Use of accessory muscles during breathing in severe cases

Diagnostic Workup


Diagnostic Criteria

Diagnosis is established by clinical presentation of fever, productive cough, and respiratory distress combined with chest imaging showing lobar consolidation. Identification of Haemophilus influenzae type b is confirmed by culture or polymerase chain reaction (PCR) from sputum, blood, or pleural fluid. Blood cultures may be positive in cases with systemic involvement. Radiographic findings and microbiological confirmation are essential for definitive diagnosis.

Pathophysiology


Key Mechanisms

  • Colonization of the upper respiratory tract by encapsulated Haemophilus influenzae type b (Hib) facilitates invasion.

  • Polysaccharide capsule of Hib prevents phagocytosis and complement-mediated lysis, enhancing virulence.

  • Inflammatory response in lung parenchyma leads to alveolar filling with exudate, causing impaired gas exchange.

  • Endotoxin release from Hib triggers local and systemic inflammation contributing to tissue damage.

  • Impaired mucociliary clearance allows bacterial proliferation and deeper lung infection.

InvolvementDetails
Organs

Lungs are the main organs affected, with consolidation and inflammation causing respiratory symptoms and impaired oxygenation.

Spleen plays a role in clearing encapsulated bacteria like Haemophilus influenzae from the bloodstream.

Tissues

Alveolar tissue is the primary site of infection and inflammation in Hib pneumonia, leading to impaired gas exchange.

Bronchial mucosa may be inflamed and contribute to airway obstruction and cough.

Cells

Alveolar macrophages phagocytose Haemophilus influenzae and initiate the innate immune response.

Neutrophils migrate to the site of infection to kill bacteria via phagocytosis and release of reactive oxygen species.

Type II pneumocytes produce surfactant and participate in alveolar repair during pneumonia.

Chemical Mediators

Tumor necrosis factor-alpha (TNF-α) promotes inflammation and recruitment of immune cells to infected lung tissue.

Interleukin-8 (IL-8) acts as a chemokine attracting neutrophils to the site of infection.

Complement system components facilitate opsonization and bacterial lysis in the alveoli.

Treatments


Pharmacological Treatments

  • Third-generation cephalosporins (e.g., ceftriaxone)

    • Mechanism:
      • Inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis.

    • Side effects:
      • Allergic reactions

      • Diarrhea

      • Elevated liver enzymes

    • Clinical role:
      • First-line

  • Amoxicillin-clavulanate

    • Mechanism:
      • Amoxicillin inhibits bacterial cell wall synthesis; clavulanate inhibits beta-lactamase enzymes produced by resistant bacteria.

    • Side effects:
      • Allergic reactions

      • Gastrointestinal upset

      • Rash

    • Clinical role:
      • First-line

  • Macrolides (e.g., azithromycin)

    • Mechanism:
      • Inhibit bacterial protein synthesis by binding to the 50S ribosomal subunit.

    • Side effects:
      • Gastrointestinal upset

      • QT prolongation

      • Hepatotoxicity

    • Clinical role:
      • Second-line

Non-pharmacological Treatments

  • Provide supplemental oxygen therapy to maintain adequate oxygen saturation in patients with hypoxemia.

  • Ensure adequate hydration and nutrition to support immune function and recovery.

  • Use mechanical ventilation in cases of respiratory failure or severe respiratory distress.

Prevention


Pharmacological Prevention

  • Hib conjugate vaccine administered in infancy to prevent invasive disease

  • Prophylactic antibiotics (e.g., rifampin) for close contacts during outbreaks

  • Appropriate antibiotic treatment of nasopharyngeal carriers in high-risk settings

  • Immunization boosters as recommended by guidelines

  • Antibiotic stewardship to reduce resistance

Non-pharmacological Prevention

  • Routine childhood immunization schedules adherence

  • Avoidance of tobacco smoke exposure to reduce respiratory tract vulnerability

  • Good hand hygiene to limit transmission

  • Isolation of infected individuals during outbreaks

  • Breastfeeding to enhance infant immune protection

Outcome & Complications


Complications

  • Lung abscess formation due to necrotizing infection

  • Empyema from pleural space infection

  • Sepsis and septic shock in severe cases

  • Respiratory failure requiring mechanical ventilation

  • Meningitis as an invasive complication of Hib

Short-term Sequelae Long-term Sequelae
  • Persistent hypoxia requiring supplemental oxygen

  • Pleural effusion development

  • Prolonged cough after resolution of acute infection

  • Hospitalization for intravenous antibiotics

  • Transient bacteremia

  • Bronchiectasis from recurrent or severe infections

  • Chronic lung scarring and fibrosis

  • Reduced pulmonary function

  • Increased risk of future respiratory infections

  • Neurological deficits if meningitis occurred

Differential Diagnoses


Pneumonia (Haemophilus influenzae type b - Hib) versus Streptococcus pneumoniae pneumonia

Pneumonia (Haemophilus influenzae type b - Hib)

Streptococcus pneumoniae pneumonia

Haemophilus influenzae type b is a gram-negative coccobacillus

Streptococcus pneumoniae is a gram-positive diplococcus

Primarily affects unvaccinated children under 5 years

Common in all age groups but especially adults and elderly

Requires third-generation cephalosporins due to beta-lactamase production

Usually sensitive to penicillin and cephalosporins

Pneumonia (Haemophilus influenzae type b - Hib) versus Mycoplasma pneumoniae pneumonia

Pneumonia (Haemophilus influenzae type b - Hib)

Mycoplasma pneumoniae pneumonia

Haemophilus influenzae has a gram-negative cell wall

Mycoplasma pneumoniae lacks a cell wall

More common in young children under 5 years

Common in school-aged children and young adults

Often causes acute, more severe pneumonia

Usually causes a gradual onset with mild symptoms (walking pneumonia)

Pneumonia (Haemophilus influenzae type b - Hib) versus Klebsiella pneumoniae pneumonia

Pneumonia (Haemophilus influenzae type b - Hib)

Klebsiella pneumoniae pneumonia

Haemophilus influenzae type b is a smaller gram-negative coccobacillus

Klebsiella pneumoniae is a gram-negative rod with thick capsule

Typically causes lobar consolidation without cavitation

Classically causes upper lobe cavitary lesions with thick, mucoid sputum

More common in unvaccinated children and immunocompromised hosts

Common in alcoholics and patients with chronic lung disease

Pneumonia (Haemophilus influenzae type b - Hib) versus Viral pneumonia (e.g., Respiratory syncytial virus)

Pneumonia (Haemophilus influenzae type b - Hib)

Viral pneumonia (e.g., Respiratory syncytial virus)

Caused by gram-negative bacteria Haemophilus influenzae type b

Caused by RNA viruses such as RSV

Presents with lobar consolidation and purulent sputum

Often presents with diffuse interstitial infiltrates and wheezing

Also affects young children but with bacterial pneumonia features

Common in infants and young children during winter months

Pneumonia (Haemophilus influenzae type b - Hib) versus Legionella pneumophila pneumonia

Pneumonia (Haemophilus influenzae type b - Hib)

Legionella pneumophila pneumonia

Haemophilus influenzae grows on chocolate agar

Legionella pneumophila is a gram-negative rod requiring special culture media

Hyponatremia is uncommon; liver enzymes usually normal

Hyponatremia and elevated liver enzymes are common

No specific environmental exposure; transmitted via respiratory droplets

Associated with contaminated water sources and air conditioning systems

Medical Disclaimer: The content on this site is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. If you think you may be experiencing a medical emergency, call 911 or your local emergency number immediately. Always consult a licensed healthcare professional with questions about a medical condition.

Artificial Intelligence Use: Portions of this site’s content were generated or assisted by AI and reviewed by Erik Romano, MD; however, errors or omissions may occur.

USMLE® is a registered trademark of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). Doctogenic and Roscoe & Romano are not affiliated with, sponsored by, or endorsed by the USMLE, FSMB, or NBME. Neither FSMB nor NBME has reviewed or approved this content. "USMLE Step 1" and "USMLE Step 2 CK" are used only to identify the relevant examinations.